The pattern of S100A6 expression in benign epithelium and adenocarcinomas is similar to that of cytokeratin 5 and that reported for p63 and 34βE12, and therefore has the potential to be used as an adjuvant to these markers in the diagnosis of prostate cancer. The gene discussed is KRT5; the disease is prostate carcinoma.